Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Hormone receptor (HR)(+) breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR(+) BC, in part reflecting the lack of preclinical models that recapitulate disease pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Buqué, Aitziber, Bloy, Norma, Perez-Lanzón, Maria, Iribarren, Kristina, Humeau, Juliette, Pol, Jonathan G., Levesque, Sarah, Mondragon, Laura, Yamazaki, Takahiro, Sato, Ai, Aranda, Fernando, Durand, Sylvère, Boissonnas, Alexandre, Fucikova, Jitka, Senovilla, Laura, Enot, David, Hensler, Michal, Kremer, Margerie, Stoll, Gautier, Hu, Yang, Massa, Chiara, Formenti, Silvia C., Seliger, Barbara, Elemento, Olivier, Spisek, Radek, André, Fabrice, Zitvogel, Laurence, Delaloge, Suzette, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393498/
https://www.ncbi.nlm.nih.gov/pubmed/32732875
http://dx.doi.org/10.1038/s41467-020-17644-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393498/
https://www.ncbi.nlm.nih.gov/pubmed/32732875
http://dx.doi.org/10.1038/s41467-020-17644-0

Ejemplares similares